Australia Markets closed

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
64.62+1.39 (+2.20%)
At close: 4:00PM EST

64.70 +0.08 (0.12%)
After hours: 6:56PM EST

Full screen
Trade prices are not sourced from all markets
Previous close63.23
Open63.42
Bid64.50 x 1800
Ask64.85 x 1100
Day's range63.30 - 64.75
52-week range56.56 - 85.97
Volume9,527,228
Avg. volume9,114,106
Market cap81.201B
Beta (5Y monthly)0.42
PE ratio (TTM)659.39
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield2.84 (4.49%)
Ex-dividend date12 Mar 2021
1y target estN/A
All
News
Press releases
  • Gilead Sciences Completes Acquisition of MYR GmbH
    Business Wire

    Gilead Sciences Completes Acquisition of MYR GmbH

    Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MYR GmbH for up to approximately €1.45 billion in aggregate cash consideration. The acquisition provides Gilead with Hepcludex® (bulevirtide), which was conditionally approved by the European Medicines Agency for the treatment of chronic hepatitis delta virus (HDV) in adults with compensated liver disease in July 2020.

  • Diodes Incorporated to Participate at the Loop Capital Markets Conference on March 11
    Business Wire

    Diodes Incorporated to Participate at the Loop Capital Markets Conference on March 11

    Diodes Incorporated (Nasdaq: DIOD), today announced Brett Whitmire, Chief Financial Officer; Emily Yang, Sr. Vice President of Worldwide Sales and Marketing; and Laura Mehrl, Director of Investor Relations, will participate in the Loop Capital Markets Virtual Consumer, Industrials & TMT Conference on Thursday, March 11, 2021. Management will be available throughout the day to host conference calls with investors participating in the event.

  • Gilead to Present New Data at CROI 2021 Demonstrating the Company's Commitment to Addressing Urgent Global Health Needs
    Business Wire

    Gilead to Present New Data at CROI 2021 Demonstrating the Company's Commitment to Addressing Urgent Global Health Needs

    Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new data from the company’s HIV, hepatitis C virus (HCV), and COVID-19 research and development programs at the 28th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2021) taking place from March 6-10. The breadth of data at the meeting reflects Gilead’s longstanding commitment to applying its scientific innovation toward addressing some of the world’s most challenging viruses and advancing global health.